Meeting
2013 ASCO Annual Meeting
Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).
Authors
Irene Brana
Princess Margaret Cancer Center, University Health Network, Division of Medical Oncology & Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Irene Brana , Kathleen N. Moore , Ronnie Shapira-Frommer , Stephen Welch , Ying-Ming Jou , Michelle Marinucci , Tomoko Freshwater , Shelonitda Rose , Amit M. Oza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01357161
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5518)
DOI
10.1200/jco.2013.31.15_suppl.5518
Abstract #
5518
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Kathleen N. Moore
Poster
2024 ASCO Annual Meeting
A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).
First Author: Bruna Pellini
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore